Quantinno Capital Management LP Grows Stock Position in Certara, Inc. $CERT

Quantinno Capital Management LP increased its position in shares of Certara, Inc. (NASDAQ:CERT) by 412.5% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 988,990 shares of the company’s stock after purchasing an additional 796,007 shares during the quarter. Quantinno Capital Management LP’s holdings in Certara were worth $5,637,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in Certara in the 1st quarter valued at $259,000. Goldman Sachs Group Inc. boosted its stake in Certara by 65.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after purchasing an additional 90,724 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Certara by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after buying an additional 35,954 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Certara by 17.1% during the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after buying an additional 40,463 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Certara by 29.3% in the second quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock valued at $1,089,000 after buying an additional 21,099 shares during the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Trading Up 1.5%

Shares of CERT opened at $8.13 on Friday. Certara, Inc. has a 12-month low of $4.45 and a 12-month high of $13.88. The firm has a market capitalization of $1.24 billion, a P/E ratio of -18.07 and a beta of 1.44. The firm has a 50-day moving average price of $6.52 and a 200 day moving average price of $6.54. The company has a current ratio of 2.55, a quick ratio of 1.88 and a debt-to-equity ratio of 0.30.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $93.27 million during the quarter, compared to analysts’ expectations of $98.09 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The business’s quarterly revenue was down 10.8% on a year-over-year basis. During the same period last year, the company earned $0.07 EPS. Sell-side analysts forecast that Certara, Inc. will post 0.24 EPS for the current year.

Wall Street Analyst Weigh In

CERT has been the subject of a number of recent research reports. Robert W. Baird cut their price objective on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, May 12th. BMO Capital Markets lowered their target price on Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings upgraded Certara from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday. KeyCorp cut their price target on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a report on Monday, April 13th. Finally, Craig Hallum reduced their price objective on Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $8.28.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.